Skip to content
Improving Survival In Oncogene Driven Lung Cancer episode artwork

Nov 10, 2020 30 min

Improving Survival In Oncogene Driven Lung Cancer

from Conversations in Lung Cancer Research Hosted by Dr. Melissa Moore, Associate Professor Tom John, Professor Ben Solomon

Join us for a conversation with internationally recognized Medical Oncologists and researchers, Professor Ben Solomon & Associate Professor Tom John as they discuss the increased survival benefits for patients with oncogene driven lung cancer and how novel treatments are contributing. Oncogenes discussed include EGFR & osimertinib; ALK & brigatinib, alectinib, lorlatinib; ROS1 & crizotinib, entrectinib; KRAS & sotorasib; G12C; Exon20 insertions & poziotinib, amivantamab, RET & selpercatinib, pralcetinib. Also discussed – the importance of the move beyond single gene testing to panels and NGS is important to maximise turn-around times and the efficient utilization of clinical samples. --------------- Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube: https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Episode details come from the podcast's RSS feed.

Embed this episode

A conversation with Associate Professor Tom John and Professor Ben Solomon where they discuss the increased survival benefits for patients with oncogene driven lung cancer and how novel treatments are contributing.

Ready to play

Improving Survival In Oncogene Driven Lung Cancer

0:00 30:16

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Conversations in Lung Cancer Research?

This episode is 30 minutes long.

When was this Conversations in Lung Cancer Research episode published?

This episode was published on November 10, 2020.

Can I download this Conversations in Lung Cancer Research episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.